Skip to main content
PULM logo

Pulmatrix, Inc. (PULM) Stock Price & Analysis

Pulmatrix, Inc. (PULM) — MoonshotScore 29/100 (Weak band), calculated Nov 18, 2026. Price $1.42 (+4.41%), as of the Nov 19, 2026 trading session; market cap $5.19M.

Educational signal · not a buy or sell recommendation · How to read this

$1.42 +$0.06 (+4.41%) Market Cap $5.19M

Pulmatrix, Inc. · PULM · NASDAQ

Pulmatrix, Inc. is a clinical-stage biotechnology company focused on developing inhaled therapies for respiratory diseases. Their iSPERSE technology aims to deliver drugs directly to the lungs for local and systemic treatment.

Price as of Nov 19, 2026

Key Statistics

29 of 100

MoonshotScore v2 · Pulmatrix (PULM)

Weak
Business Quality Thin (22)
Financial Safety Fragile (18)
Valuation Bubble (4)
Growth Durability Flat (45)
Momentum Quiet (42)
Why this rating? Method, drivers & history

Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.

  • Business Quality — Is this a genuinely good business?
  • Financial Safety — Could this blow up on me?
  • Valuation — Am I paying a fair price?
  • Growth Durability — Is the growth real and likely to last?
  • Momentum — Is the market already moving on this?
The ten-second read ·

Bottom-tier quality, a fragile balance sheet and an expensive valuation, though growth is only middling. The score also carries a risk penalty for a bankruptcy-risk score in the distress zone. Business Quality: Thin; Financial Safety: Fragile; Valuation: Bubble; Growth Durability: Flat; Momentum: Quiet.

Free cash flow yield is the main valuation drag relative to sector peers.

  • EPS beat 7 of the last 8 reports

Holding back: weak fundamentals, balance-sheet strain, a rich price

What has the MoonshotScore done over time?

MoonshotScore snapshots recorded for PULM (57 recorded, newest six shown)
RecordedScoreBand
31Weak
28Weak
29Weak
29Weak
29Weak
29Weak

Daily score refresh is delayed. This is the last recorded calculation.

Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.

Computed · How the MoonshotScore is computed →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$1.42
Change on the day+4.41%
52-week range$1.06 – $4.98
Market capitalisation$5.19M—
Shares traded on the day172.6K

Price & events

Other perspectives

Council score for Pulmatrix (PULM): perspectives

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

5-Factor Breakdown

Business Quality Weak
Financial Safety Negative
Valuation Negative
Growth Durability Neutral
Momentum Neutral

Legends Council

3 lenses, 0 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Englander-style lens (simulated) Izzy Englander Unfavorable read
Klarman-style lens (simulated) Seth Klarman Unfavorable read
Moon AI lens (model) Unfavorable read

Read on: Oct 11, 2026 · older than the 27 hours refresh window; not a current reading

Munger's Mindset

Balance Sheet & Valuation · historical

Financial Health Neutral
Margin of Safety Fairly Valued
Revenue Growth Negative

Read on: Sep 2, 2026 · older than the 27 hours refresh window; not a current reading

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

On Sep 2, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.

Readings on this page are from Nov 20, 2026, except a card that shows its own read date.

1 · What is it?

What is Pulmatrix (PULM), and what does it report?

Short answer

A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Pulmatrix, Inc. (PULM) is listed on NASDAQ. It employs 2 people and is led by Peter Ludlum. The market values it at $5.19M.

2 · Latest results

What do the latest results show for Pulmatrix (PULM)?

Short answer · as of

Against analyst estimates the company has EPS beat 7 of the last 8 reports.

3 · Financial strengths and risks

What are the financial strengths and risks for Pulmatrix (PULM)?

Short answer · as of

What is holding it back is weak fundamentals, balance-sheet strain, a rich price. The distress and quality screens read Piotroski F 1. Trailing ratios: current ratio 4.70 · earnings yield -74.2% · free-cash-flow yield -72.3%.

4 · What to check next?

What should you watch next at Pulmatrix (PULM)?

Short answer · as of

Analyst estimates on file carry FY2026 revenue $16.45M · EPS -2.24 · 1 analysts.

What the records here don't tell us

  • The next earnings date is not yet scheduled in the calendar we read.
  • No insider Form 4 transaction falls inside the window this page reads.
  • No quarterly income statement is held for PULM.

Checked against the records this page reads, on the dates shown above.

5 · Peer comparison

How does Pulmatrix compare with its peers?

Short answer

Pulmatrix's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.

Peer set — price, market value and MoonshotScore
CompanyPriceMarket valueScore
Fennec Pharmaceuticals Inc. (FENC) Same industry, near in market value$13.33 Nov 18, 2026$471M91 5-pillar Nov 18, 2026
Zevra Therapeutics, Inc. (ZVRA) Same industry, near in market value$9.28 Nov 18, 2026$552M91 5-pillar Nov 18, 2026
Protalix BioTherapeutics, Inc. (PLX) Same industry, near in market value$3.06 Nov 19, 2026$258M90 5-pillar Nov 18, 2026
Rigel Pharmaceuticals, Inc. (RIGL) Same industry, near in market value$42.53 Nov 18, 2026$801M88 5-pillar Nov 18, 2026
Rallybio Corporation (RLYB) Same industry, near in market value$15.26 Nov 18, 2026$85.5M82 5-pillar Nov 18, 2026
ImmuCell Corporation (ICCC) Same industry, near in market value$11.25 Nov 18, 2026$102M82 5-pillar Nov 18, 2026
Oramed Pharmaceuticals Inc. (ORMP) Same industry, near in market value$3.89 Nov 18, 2026$169M72 5-pillar Nov 18, 2026
Compugen Ltd. (CGEN) Same industry, near in market value$1.88 Nov 19, 2026$178M69 5-pillar Nov 18, 2026
Climb Bio, Inc. (CLYM) Same industry, near in market value$9.30 Nov 18, 2026$546M68 5-pillar Nov 18, 2026
MeiraGTx Holdings plc (MGTX) Same industry, near in market value$8.14 Nov 19, 2026$796M63 5-pillar Nov 18, 2026
Indaptus Therapeutics, Inc. (INDP) Same industry, near in market value$3.13 Nov 19, 2026$481M60 5-pillar Nov 18, 2026
Cybin Inc. (HELP) Same industry, near in market value$6.78 Nov 19, 2026$541M60 5-pillar Nov 18, 2026
Pulmatrix (PULM) — this page$1.42$5.19M29

Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.

The records behind this page

Analyst targets & estimates

What analysts have on file

Revenue estimate
$16.45M
EPS estimate
$-2.24

Measured against a quoted price of $1.42 (as of Nov 19, 2026).

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held PULM in their latest 13F filing, and what they did against the filing before it.

None of the 16 tracked investors reported PULM in their latest 13F filing.

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

What has been published about Pulmatrix (PULM)?

Read these with our analysis →

Investor Questions: PULM Stock

These answers are editorial: 1 of these 9 answers is drawn from the PULM research dossier (written Mar 17, 2026 by gemini-2.0-flash); the other 8 are question templates that restate figures shown above. Figures in this section are not part of the source register.

What does the MoonshotScore mean for PULM?

PULM carries the MoonshotScore stated above — the Weak band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers. Pulmatrix, Inc. is a clinical-stage biotechnology company focused on developing inhaled therapies for respiratory diseases.

Is PULM a good stock to buy?

Stock Expert AI does not rate PULM buy, sell or hold. Pulmatrix, Inc. carries a MoonshotScore, in the Weak band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.

What is the PULM stock price today?

The last price recorded for Pulmatrix, Inc. (PULM), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What do analysts say about PULM stock?

However, as a clinical-stage biotechnology company, Pulmatrix's valuation is largely driven by the potential of its pipeline candidates and the success of its iSPERSE technology.

What are the key factors to evaluate for PULM?

Pulmatrix, Inc. (PULM) holds a MoonshotScore in the low range. This would require further research and development efforts, but could significantly increase the long-term value of the company. Not financial advice.

How frequently does PULM data refresh on this page?

PULM's price is the last quote we recorded, from the Nov 19, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.

What has driven PULM's recent stock price performance?

Pulmatrix, Inc. (PULM) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary iSPERSE technology for targeted drug delivery. See the News tab for the latest drivers. Past performance does not predict future results.

Should investors consider PULM overvalued or undervalued right now?

Pulmatrix, Inc. (PULM) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.

Can I buy fractional shares of PULM?

Fractional-share availability for Pulmatrix, Inc. (PULM) depends on your brokerage, account and supported securities. Check the broker's current eligibility, minimums and fees before placing an order.

Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 17, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 16 figures on this page — 4 from Financial Modeling Prep (FMP), 10 with no recorded source and 2 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.